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the sensitivity and specificity of the MTD test; the proportion of smear-positive specimens containing detectable MTD inhibitors; and the proportion of smear-positive respiratory specimens that was culture-positive for M. tuberculosis.
These parameters, along with the estimates listed below, formed the principal effectiveness parameters used by the model.
Study designs and other criteria for inclusion in the review
For inclusion in the review, the studies had to report sufficient data to determine the sensitivity and specificity of the MTD in smear-positive respiratory specimens. The validity of the MTD test was determined using culture as the 'gold' standard, or culture plus clinical criteria when reported.
Sources searched to identify primary studies
MEDLINE was searched for primary studies.
Criteria used to ensure the validity of primary studies
TB status was determined by culture result, combined with clinical criteria when reported. The estimation of MTD validity measures considered only smear-positive specimens. It was assumed that the MTD strategy was run on the first smear-positive respiratory specimen submitted from any patient in whom a diagnosis of mycobacterial disease had not been made in the previous 30 days. Samples found to contain MTD-inhibitory substances were considered to provide insufficient evidence for the exclusion of M. tuberculosis and were not re-tested. Two studies used a different diagnostic algorithm, whereby MTDs giving results between 30,000 and 500,000 relative light units were re-tested. The sensitivity and specificity were reported after the removal of specimens with MTD inhibitors.
Methods used to judge relevance and validity, and for extracting data
Not stated.
Number of primary studies included
Nine primary reports were included in the review.
Methods of combining primary studies
The mean values for sensitivity and specificity were determined from the included studies.
Investigation of differences between primary studies
Not reported. When considering only smear-positive specimens, the analysis of compiled studies from the literature review indicated an overall sensitivity of 99.6% (91.8, 100) and specificity of 99.7% (95, 100).
Results of the review
The proportion of smear-positive specimens containing detectable MTD inhibitors was 0% (without TB) or 2.3% (with TB) (0, 7.2).
The proportion of smear-positive respiratory specimens that were culture-positive for M. tuberculosis was 31.4% (25, 
Methods used to derive estimates of effectiveness
The estimates were derived from records at the authors' hospital.
Estimates of effectiveness and key assumptions
The annual number of MTD-candidate patients submitting smear-positive respiratory samples was 14 (1, 500). The relative prevalence of TB among individuals with smear-positive respiratory specimens, as well as the average length of time between the smear and culture results, was ascertained directly using data from the hospital's clinical microbiology laboratory. This facility processed 4,607 specimens for mycobacterial culture in 2001. The records of all smear-or culture-positive specimens submitted from patients who provided at least one smear-positive sample to the hospital between 1996 and 2001 inclusive were evaluated. Eighty-two specimens met these criteria and were used for this analysis. The presence or absence of co-morbid conditions, such as human immunodeficiency virus and acquired immune deficiency syndrome, was not ascertained.
Measure of benefits used in the economic analysis
The outcome measure used in the economic analysis was the number of early TB exclusions. "Early exclusion of TB" was defined as the proper exclusion of M. tuberculosis as the etiologic agent of smear-positive respiratory disease on the basis of the MTD results.
Direct costs
The estimated costs of MTD detection reagents (kits of 50 tests), training sessions for new technicians, technician time for MTD, supplies, drug costs, patient respiratory isolation, HEPA filters (two annually) and pre-filter changes, and the costs of control samples maintained in the laboratory, were summarised for January 2000 to December 2001. The quantities and the costs were not analysed separately. The marginal costs of personal protective equipment (masks) and additional costs for proficiency testing were not included in this analysis. An annual discount rate of 5% per year was reported only for the cost amortised for the negative-pressure isolation room. The price year was 2001.
Statistical analysis of costs
No statistical analysis of the costs was reported.
Indirect Costs
No indirect costs were included in the analysis.
Currency
US dollars ($).
Sensitivity analysis
One-way sensitivity analyses were performed for all variables, except the drug costs. The ranges used were derived from literature reports covering a range of reasonable possibilities (see 'Results of the Review' and 'Estimates of Effectiveness' sections). If one-way variation of a variable throughout its entire range did not change the estimated MTD cost-effectiveness by more than 10%, the analysis was reported as insensitive to that variable.
A three-way sensitivity analysis (marginal MTD cost/patient, number of early TB exclusions/100 patients and cost/early exclusion of TB) was carried out on the relative prevalence of TB, the annual number of specimens processed and the marginal cost of respiratory isolation. The relative prevalence of TB in smear-positive patients was evaluated using a range of 25 to 98.4% for the sensitivity analysis. The cost of labour was evaluated using a range of $15 to 35/hour.
Estimated benefits used in the economic analysis
Full details of the results were tabulated in the paper (table 3) . The following provide a representative sample.
The number of early TB exclusions/100 patients with the MTD was 68 in the base-case.
For the sensitivity analysis of the relative prevalence of TB in smear-positive patients, the number of early TB exclusions/100 patients with the MTD was 75 when assuming a rate of 25%. When this rate was assumed to be over 50%, the number of early TB exclusions/100 patients with the MTD was successively decreased to 2 with a prevalence rate of 98.4%.
When the number of smear-positive specimens processed annually by the MTD was varied over a range from 1 to 500, the number of early TB exclusions/100 patients with MTD test was always 68.
Cost results
In the base-case, the marginal MTD cost per patient was $338 and the cost per early exclusion of TB was $494. The cost of isolation plus presumptive therapy for a base-case was calculated to be $201.
When the relative prevalence of TB in smear-positive patients was in the range 25 to 75 %, the marginal MTD cost per patient was $338, but the cost of early exclusion of TB increased from $452 to $1,355. A prevalence rate over 90% had a small effect in decreasing the marginal MTD cost for patient, but had a higher impact on increasing the cost of early exclusion of TB.
Maintaining the number of early TB exclusions/100 patients constant at 68 (as in the base-case), when one smearpositive specimen/year was processed by MTD, the marginal MTD cost per patient was $2,564 and the cost of early exclusion of TB was $3,750. With the same condition, when the annual number of smear-positive specimens processed by MTD was in the range 10 to 500, the marginal MTD cost per patient varied between $407 and $114, and the cost of early exclusion of TB varied from $595 to $168. 
Synthesis of costs and benefits
The estimated benefits and costs were combined as the cost per early exclusion of TB and an incremental analysis was not performed. The MTD was not cost-effective in the base-case. A routine MTD testing programme is expected to cost $494 per early exclusion of TB. By contrast, the expected cost of isolation plus presumptive therapy was $201.
The cost-effectiveness of MTD testing was highly sensitive to changes in the relative prevalence of TB in smearpositive specimens, the number of specimens processed per year, and the marginal daily cost of respiratory isolation. Further, the estimates of savings depended heavily on the marginal daily cost of respiratory isolation, and the speed with which MTD and culture results would become available. The model was not sensitive to changes in MTD sensitivity, specificity, or probability of inhibition (less than 10% change in cost-effectiveness across the range of the variable).
